Home › Trials › NCT07213973

Povorcitinib for adolescents with moderate to severe hidradenitis suppurativa

A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa

PHASE2 · Incyte Corporation · NCT07213973

This trial tests the oral drug povorcitinib in adolescents aged 12–17 with moderate to severe hidradenitis suppurativa to see if it is safe, how the body handles it, and whether it reduces lesions over a 54-week treatment period.

Quick facts

PhasePHASE2
Study typeInterventional
Enrollment40 (estimated)
Ages12 Years to 17 Years
SexAll
SponsorIncyte Corporation (industry)
Drugs / interventionspovorcitinib
Locations27 sites (Birmingham, Alabama and 26 other locations)
Trial IDNCT07213973 on ClinicalTrials.gov

What this trial studies

This Phase 2 open-label trial gives adolescents with moderate to severe hidradenitis suppurativa oral povorcitinib for up to 54 weeks to measure pharmacokinetics, safety, and clinical response. Eligible participants are 12–17 years old, weigh at least 30 kg, have at least five abscesses or inflammatory nodules and meet refined Hurley stages IB–III, and must have a history of inadequate response or intolerance to prior systemic therapy. The protocol involves regular clinic visits for lesion counts, laboratory monitoring, and adverse event reporting at participating sites. There is no placebo arm and dosing and monitoring follow the trial protocol.

Who should consider this trial

Good fit: Ideal candidates are adolescents aged 12–17 years, weighing at least 30 kg, with moderate to severe HS (≥5 abscesses/inflammatory nodules and refined Hurley stages IB–III) who have had an inadequate response or intolerance to at least one conventional systemic therapy.

Not a fit: Patients with very advanced disease who have more than 20 draining tunnels, children younger than 12 or adults 18 and older, or those weighing less than 30 kg are not eligible and therefore would not receive benefit from participating in this protocol.

Why it matters

Potential benefit: If successful, povorcitinib could provide an effective oral option to reduce lesions and symptoms in adolescents with moderate to severe HS.

How similar studies have performed: Adult trials of JAK1 inhibitors, including earlier studies of povorcitinib, have shown promising efficacy and safety signals in HS, but pediatric data are limited.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Aged ≥ 12 to \< 18 years at the time of informed consent/assent signing.
* Body weight ≥ 30 kg at both screening and baseline visits.
* Diagnosis of moderate to severe HS for at least 3 months prior to the screening visit.
* Total abscess and inflammatory nodule count of at least 5 at both the screening and baseline visits.
* HS lesions corresponding to refined Hurley Stage IB, IC, IIB, IIC, or III at both the screening and baseline visits.
* Documented history of inadequate response to at least a 3-month course of at least 1 conventional systemic therapy (oral antibiotic or biologic drug) for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for treatment of their HS).
* Agreement to use contraception.
* Willing and able to comply with the study protocol and procedures.
* Further inclusion criteria apply.

Exclusion Criteria:

* Presence of \> 20 draining tunnels (fistulas) at either the screening or baseline visit.
* Women who are pregnant (or who are considering pregnancy) or breastfeeding.
* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
* Laboratory values outside of the protocol-defined ranges.
* Further exclusion criteria apply.

Where this trial is running

Birmingham, Alabama and 26 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Hidradenitis Suppurativa, HS, INCB054707, Povorcitinib, Acne inversa, Hidradenitis

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.